These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Response of patients with postencephalitic Parkinsonism to levodopa. Duvoisin RC; Lobo-Antunes J; Yahr MD J Neurol Neurosurg Psychiatry; 1972 Aug; 35(4):487-95. PubMed ID: 5049808 [TBL] [Abstract][Full Text] [Related]
12. Abnormal mouth-movements and oral damage associated with L-DOPA treatment. Sacks OW; Ross SJ; DePaola DP; Kohl MS Ann Dent; 1970; 29(4):130-44. PubMed ID: 5275661 [No Abstract] [Full Text] [Related]
13. [Psychic manifestations during treatment of Parkinson's disease with L-dopa]. Bonduelle M Rev Neurol (Paris); 1970 Feb; 122(2):140. PubMed ID: 5517897 [No Abstract] [Full Text] [Related]
14. Respiratory disturbance during L-dopa treatment of Parkinson's syndrome. Granerus AK; Jagenburg R; Nilsson NJ; Svanborg A Acta Med Scand; 1974; 195(1-2):39-43. PubMed ID: 4817091 [No Abstract] [Full Text] [Related]
15. [Study of L-dopa treatment and its principal side effects in aged subjects]. Antonini F; Baroni A; Bucalossi A; Roveyaz L Gerontol Clin (Basel); 1972; 14(5):297-309. PubMed ID: 4144357 [No Abstract] [Full Text] [Related]
16. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine]. Sigwald J; Raymondeaud C; Piot C Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718 [No Abstract] [Full Text] [Related]
17. [L-Dopa therapy in Parkinson's disease. A double-blind study]. Worm-Petersen J; Dupont E; Mikkelsen B Ugeskr Laeger; 1971 Nov; 133(47):2321-6. PubMed ID: 4944651 [No Abstract] [Full Text] [Related]
18. Long-term effects of levodopa in the severely disabled patient. Sacks OW; Messeloff CR; Schwartz WF JAMA; 1970 Sep; 213(13):2270. PubMed ID: 5468938 [No Abstract] [Full Text] [Related]